STOCK TITAN

IN8bio Inc - INAB STOCK NEWS

Welcome to our dedicated news page for IN8bio (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on IN8bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IN8bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IN8bio's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.98%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.58%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.16%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.95%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.17%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.57%
Tags
IN8bio Inc

Nasdaq:INAB

INAB Rankings

INAB Stock Data

48.05M
24.46M
15.97%
37.34%
0.12%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
New York

About INAB

in8bio, inc. (“in8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.